Table 3.
Antiviral activity of compounds against orthopoxvirus replication with phase II/phase III history
| Drug | Indication | Sponsor | EC50 (μM) |
|
| VV | CV | |||
| Adefovir | HIV/HBV | Gilead Sciences | >300 | >300 |
| Adefovir dipivoxil | HIV/HBV | Gilead Sciences | 5.1 | 13 |
| Amdoxovir | HIV | Triangle | >300 | >300 |
| Clevudine | HBV | Triangle | >300 | >300 |
| Coactinon | HIV | Triangle | >300 | >300 |
| Coviracil | HBV/HIV | Triangle | >81 | >81 |
| Emivirine | HIV | Triangle | >300 | >300 |
| Entecavir | HBV | Bristol-myers squibb | 53 | 85 |
| Fialuridine | HBV-CMV | Eli Lilly | 1.5 | 0.24 |
| Lobucavir | HIV/HSV | Bristol-myers squibb | 27 | 66 |
| Mozenavir | HIV | Triangle | >100 | >100 |
| Sorivudine | HSV/VZV | Bristol-myers squibb | >100 | >100 |